EMEugen F. Mesaros

Eugen F. Mesaros

*This is an algorithmically generated author record based on publicly available information.

Eugen F. Mesaros has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus

    by Angela M. Lam, Nagraj Mani, Andrzej Ardzinski, Kim Stever, Andrea Cuconati, Holly Micolochick Steuer, Emily P. Thi, Ingrid E. Graves, Christine L. Espiritu, Eugen Mesaros, et al.


  • Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836

    by Andrew G. Cole, Steven G. Kultgen, Nagraj Mani, Kristi Yi Fan, Andrzej Ardzinski, Kim Stever, Bruce D. Dorsey, Eugen F. Mesaros, Emily P. Thi, Ingrid Graves, et al.

    Inhibition of Hepatitis B Virus (HBV) replication by small molecules that modulate capsid assembly and the encapsidation of pgRNA and viral polymerase by HBV core protein is a clinically validated approach toward the development of new antivirals. Through definition of a minimal pharmacophore, a series of isoquinolinone-based capsid assembly modulators (CAMs) was identified. Structural biology analysis revealed that lead molecules possess a unique binding mode, exploiting electrostatic interactions with accessible phenylalanine and tyrosine residues. Key analogs demonstrated excellent primary potency, absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic properties, and efficacy in a mouse model of HBV. The optimized lead also displayed potent inhibition of capsid uncoating in HBV-infected HepG2 cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP) receptor, affecting the generation of HBsAg and cccDNA establishment. Based on these results, isoquinolinone derivative AB-836 was advanced into clinical development. In Phase 1b trials, AB-836 demonstrated >3 log10 reduction in serum HBV DNA, however, further development was discontinued due to the observation of incidental alanine aminotransferase (ALT) elevations.


  • Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators

    by Eugen F. Mesaros, Andrew G. Cole, Steven G. Kultgen, Nagraj Mani, Kristi Yi Fan, Benjamin J. Dugan, Andrzej Ardzinski, Kim Stever, Holly M. Micolochick Steuer, Ingrid Graves, et al.

    Isoquinolinone-based HBV capsid assembly modulators that bind at the dimer:dimer interface of HBV core protein have been shown to suppress viral replication in chronic hepatitis B patients. Analysis of their binding mode by protein X-ray crystallography has identified a region of the small molecule where the application of a constraint can lock the preferred binding conformation and has allowed for further optimization of this class of compounds. Key analogues demonstrated single digit nM EC50 values in reducing HBV DNA in a HepDE19 cellular assay in addition to favorable ADME and pharmacokinetic properties, leading to a high degree of oral efficacy in a relevant in vivo hydrodynamic injection mouse model of HBV infection, with 12e effecting a 3 log10 decline in serum HBV DNA levels at a once daily dose of 1 mg/kg. Additionally, maintenance of activity was observed in clinically relevant HBV core protein variants T33N and I105T.


  • Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2

    by Eugen F. Mesaros, Benjamin J. Dugan, Min Gao, Muhammad Sheraz, Kayleigh McGovern-Gooch, Fran Xu, Kristi Yi Fan, Duyan Nguyen, Steven G. Kultgen, Aaron Lindstrom, et al.

    The recent COVID-19 pandemic underscored the limitations of currently available direct-acting antiviral treatments against acute respiratory RNA-viral infections and stimulated major research initiatives targeting anticoronavirus agents. Two novel nsp5 protease (MPro) inhibitors have been approved, nirmatrelvir and ensitrelvir, along with two existing nucleos(t)ide analogues repurposed as nsp12 polymerase inhibitors, remdesivir and molnupiravir, but a need still exists for therapies with improved potency and systemic exposure with oral dosing, better metabolic stability, and reduced resistance and toxicity risks. Herein, we summarize our research toward identifying nsp12 inhibitors that led to nucleoside analogues 10e and 10n, which showed favorable pan-coronavirus activity in cell-infection screens, were metabolized to active triphosphate nucleotides in cell-incubation studies, and demonstrated target (nsp12) engagement in biochemical assays.